Research programme: anti-CD4 positive T cell imaging - ImaginAb/Novotectid

Drug Profile

Research programme: anti-CD4 positive T cell imaging - ImaginAb/Novotectid

Latest Information Update: 22 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImaginAb Inc; Novotectid
  • Developer ImaginAb Inc
  • Class Antibody diagnostics; Imaging agents
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 17 Sep 2014 Preclinical trials in Cancer (Diagnosis) in USA (Parenteral)
  • 17 Sep 2014 Preclinical trials in Crohn's disease (Diagnosis) in USA (Parenteral)
  • 17 Sep 2014 Preclinical trials in Rheumatoid arthritis (Diagnosis) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top